Clinicopathological characteristics of upper tract urothelial cancer with loss of immunohistochemical expression of mismatch repair proteins in universal screening



Tetsutaro Hayashi¹, Ikeda Kenichiro¹, Keisuke Goto¹, Shogo Inoue¹, Jun Teishima¹, Kazuhiro Sentani², Daiki Taniyama², Shintaro Akahane², Wataru Yasui², Hideki Yamamoto³, Kazuya Kuraoka³, Ryan S Hsi⁴, Takao Hinoi⁵ and Akio Matsubara¹

The Department of Urology¹, Molecular Pathology², Medical genetics⁵, Hiroshima University The Department of pathology³, Kure Medical Center,

The Department of Urology⁴, Vanderbilt University Medical Center






BACKGROUNDS and OBJECTIVES

- Upper tract urothelial cancer (UTUC) is the third most frequent cancer in Lynch syndrome (LS), but little is known about the prevalence and clinical features of LS-associated UTUC.
- We studied the expression of mismatch repair (MMR) proteins in immunohistochemistry and examined the pathological characteristics of MMR deficient UTUC.

RESULTS

MMR deficient tumor was detected in 15 / 118 (13%) of UTUC cases.



Factors	MMR deficient	MMR normal	P-value
Age	65.7 ± 9.6	71.8 ± 10.0	0.0256
History of	9 (60%)	32 (34%)	0.0830
cancer	6	62	
NLR	1.88 ± 0.62	2.55 ± 1.12	0.0377


Patients with deficient MMR UTUC were younger and showed lower NLR (Neutrophil to Lymphocyte ratio).

UC, G2, pT1: Loss of MSH2/MSH6

Clinico-pathological characteristics of MMR deficient UTUC

P-value

Cancer specific survival (CSS)



MMR

normal

MMR

deficient

Factors

We identified a prevalence of 13% of UTUC cases with potential Lynch syndrome. Patients with MMR deficient UTUC associated with younger age and lower NLR, and had better CSS. Tumors with deficient MMR were associated with less pathological aggressive features with infiltration of CD8 positive lymphocytes. These findings suggest that determining MMR status may be helpful for clinicaldecision making among patients with UTUC.